Galera Therapeutics, Inc. (GRTX)

Galera Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cost of Revenue	0.26	0.11	0.78	0.37	0.27
Gross Profit	-0.26	-0.11	-0.78	-0.37	-0.27
Selling, General & Admin	22.58	20.21	20.95	15.71	8.36
Research & Development	24.12	31.01	52.42	54.85	42.33
Other Operating Expenses	0	-11.07	-7.17	-3.68	-1.25
Operating Expenses	46.69	51.23	73.37	70.55	50.69
Operating Income	-46.95	-51.23	-73.37	-70.55	-50.69
Interest Income	1.6	0.51	0.03	1.17	1.82
Interest Expense	-11.41	11.57	7.19	4.88	3.03
Other Expense / Income	25.14	0	0	-0.03	0.04
Pretax Income	-59.08	-62.29	-80.53	-74.23	-51.94
Income Tax	0	-0.07	7.19	-0.02	-0.01
Net Income	-59.08	-62.22	-87.73	-74.22	-51.93
Shares Outstanding (Basic)	45	27	26	25	25
Shares Outstanding (Diluted)	45	27	26	25	25
Shares Change	64.47%	5.03%	3.70%	0.23%	28.15%
EPS (Basic)	-1.33	-2.30	-3.40	-2.98	-2.09
EPS (Diluted)	-1.33	-2.30	-3.40	-2.98	-2.09
Free Cash Flow	-44.91	-43.45	-68.24	-59.99	-47.29
Free Cash Flow Per Share	-1.01	-1.60	-2.65	-2.41	-1.91
EBITDA	-46.69	-51.23	-72.56	-70.55	-50.69
Depreciation & Amortization	0.26	0.11	0.78	0.37	0.27
EBIT	-46.95	-51.34	-73.34	-70.92	-50.96

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.